RET and non-small cell lung carcinoma: In our study, the findings associated with the clinical outcomes related to the TTD, TTP, TTNT-D, and ORR favoring selpercatinib versus standard therapies or MKIs also support selpercatinib’s role as the frontline therapy for RET-activated NSCLC and MTC.